AGIOS PHARMACEUTICALS, INC. (AGIO) earnings date
Feb 11, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 67% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 31 days, typically, give or take 6 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | before open | 36 | 8-K |
| Q2 FY2026 | Thu, Jul 30, 2026 | before open | 30 | 8-K |
| Q1 FY2026 | Wed, Apr 29, 2026 | before open | 29 | 8-K |
| Q4 FY2025 | Thu, Feb 12, 2026 | before open | 43 | 8-K |
| Q3 FY2025 | Thu, Oct 30, 2025 | before open | 30 | 8-K |
| Q2 FY2025 | Thu, Jul 31, 2025 | before open | 31 | 8-K |
| Q1 FY2025 | Thu, May 1, 2025 | before open | 31 | 8-K |
| Q4 FY2024 | Thu, Feb 13, 2025 | before open | 44 | 8-K |
What they guided beta
| Q3 FY2026 | "$907.0 million in cash, cash equivalents, and marketable securities as of September 30, 2026, fully funding commercial launches and pipeline programs; company is targeting non-GAAP profitability in 2028 CAMBRIDGE, Mass. , Nov. 5, 2026 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the third quarter ended September 30, 2026." exhibit |
| Q3 FY2026 | "The company expects the associated cost savings of these reductions to be realized in 2027." exhibit |
| Q2 FY2026 | "The addition of cevidoplenib diversifies Agios’ rare hematology portfolio and represents an opportunity to unlock up to $1.0 billion in peak U.S. sales potential in this indication. o Agios expects to advance cevidoplenib into Phase 3 development for ITP in the first half of 2028, following completion of additional chemistry, manufacturing, and controls (CMC) development work." exhibit |
| Q2 FY2026 | "Based on these results, Agios will advance AG-236 into a Phase 2/3 development program in polycythemia vera, with initiation of the Phase 2 portion expected in the second half of 2026." exhibit |
| Q2 FY2026 | "Data from this trial are expected in the second half of 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/AGIO
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/AGIO
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/AGIO/"><img src="https://veritasdata.dev/embed/AGIO.svg" alt="AGIO earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/AGIO/)
Script
<script async src="https://veritasdata.dev/embed/AGIO.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/AGIO"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.